The US FDA has authorised Eli Lilly’s Mounjaro to be marketed for reducing major cardiovascular events in adults with type 2 diabetes at elevated risk, marking a significant milestone in incretin medicine approvals and cardiometabolic treatment strategies.
US regulators have widened Mounjaro’s label, allowing Eli Lilly to market the weekly tirzepatide injection not only for blood-sugar control but also for cutting the risk of heart-related emergencies in adults with type 2 diabetes who face elevated cardiovascular danger. The 28 August decision gives Mounjaro its first explicit cardiovascular-risk claim and, as BioPharm International noted, makes it the first dual GIP/GLP-1 receptor agonist to win such an indication. For Lilly, it also means the medicine now competes more directly in a field where heart-outcomes data can matter as much as glucose lowering.
The FDA’s supplement approval letter shows the change was broader than the headline indication alone. In the agency’s wording, Mounjaro may now be used to reduce the risk of major adverse cardiovascular events, defined as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, in high-risk adults with type 2 diabetes. The same action, effective on the date of the letter, also revised dosing language so the 2.5 mg strength can be used for ongoing glycaemic control, and updated the warnings section on diabetic retinopathy complications for patients with a history of retinopathy.
Before this change, the official US label described Mounjaro as a dual GIP and GLP-1 receptor agonist used alongside diet and exercise to improve glycaemic control in adults and in children aged 10 and over with type 2 diabetes. That earlier labelling also set out the safety backdrop against which any wider use has to be judged, including warnings on severe gastrointestinal reactions, low blood sugar when used with insulin or insulin secretagogues, and acute gallbladder disease. The new heart-risk claim therefore sits on top of an already established diabetes approval rather than replacing the medicine’s original role.
The evidence behind the expansion came from SURPASS-CVOT, a large late-stage study that Pharmacy Times said enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease across 640 sites in 30 countries. Lilly has described it as the first cardiovascular outcomes trial to compare two incretin medicines directly instead of testing one against placebo. That matters because the approved label uses broader wording, adults at high risk of major cardiovascular events, while the trial itself was run in people with clear pre-existing vascular disease.
The headline results were solid enough for the FDA, but not a clear-cut clinical rout. BioPharm International, citing the full New England Journal of Medicine paper, reported that 12.2% of patients given tirzepatide experienced cardiovascular death, heart attack or stroke during a median follow-up of four years, compared with 13.1% of those given dulaglutide, the active ingredient in Trulicity. The estimated hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01, meaning the study met the statistical bar for non-inferiority but not for superiority. Dulaglutide was used as the comparator because, after earlier evidence including the REWIND trial, a placebo-only control was considered ethically hard to justify in such high-risk patients.
That nuance is important in a crowded market. TCTMD pointed out that semaglutide already holds US cardiovascular-risk reduction indications in two separate settings: as Ozempic for adults with type 2 diabetes and established cardiovascular disease, based on SUSTAIN-6, and as Wegovy for adults without diabetes who have established cardiovascular disease plus obesity or overweight, based on SELECT. Mounjaro’s new claim does not give Lilly the field to itself, but it does give tirzepatide a regulatory foothold in the same outcomes-driven contest that has helped reshape prescribing, reimbursement debates and cardiologists’ interest in incretin drugs.
Lilly has been quick to frame the decision in practical terms for patients. Kenneth Custer, the company’s cardiometabolic health president, said in remarks reported by AJMC that “heart disease is the leading cause of death” for people with type 2 diabetes and described Mounjaro as “the number 1 most prescribed branded type 2 diabetes medicine for adults in the US”. Pharmacy Times said the company also presented the approval as a treatment option that can address cardiovascular risk alongside glucose control, underscoring how drugmakers increasingly market these therapies on several fronts at once: blood sugar, weight and now major cardiac outcomes.
The regulatory paperwork suggests Lilly’s next task is not a fresh efficacy fight but implementation. The FDA told the company to submit updated structured product labelling within 14 days and to bring promotional materials into line with the revised prescribing information, including the new safety wording. The agency also waived a paediatric study requirement for the new cardiovascular indication, saying the condition for which the supplement was approved rarely or never occurs in paediatric populations. For clinicians, the immediate consequence is simpler: a medicine already familiar in diabetes care can now be prescribed in the US with a formal claim to lower the risk of the events patients most fear.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
